var data={"title":"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/contributors\" class=\"contributor contributor_credentials\">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/contributors\" class=\"contributor contributor_credentials\">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alpha-1 antitrypsin (AAT) deficiency is a clinically under-recognized inherited disorder affecting the lungs, liver, and rarely, skin. In the lungs, AAT deficiency causes chronic obstructive pulmonary disease (ie, emphysema and bronchiectasis).</p><p>The pulmonary manifestations, diagnosis, and natural history of this disorder will be reviewed here [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/1-5\" class=\"abstract_t\">1-5</a>]. Extrapulmonary disease and therapy are discussed separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;</a> and <a href=\"topic.htm?path=treatment-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Treatment of alpha-1 antitrypsin deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H346591381\"><span class=\"h1\">BACKGROUND</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AAT is a protease inhibitor (Pi) of the proteolytic enzyme elastase and also of the proteases trypsin, chymotrypsin, and thrombin [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/6\" class=\"abstract_t\">6</a>]. It is part of a larger family of structurally unique <strong>ser</strong>ine <strong>p</strong>rotease <strong>in</strong>hibitors, referred to as serpins, which have also been implicated in the pathogenesis of neurodegenerative diseases, angioedema, and coagulation abnormalities, collectively called &quot;serpinopathies&quot; [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/4,7\" class=\"abstract_t\">4,7</a>]. </p><p>Emphysema in AAT deficiency (AATD) is thought to result from an imbalance between neutrophil elastase in the lung, which destroys elastin, and the elastase inhibitor AAT, which protects against proteolytic degradation of elastin. This mechanism is called a &quot;toxic loss of function.&quot; Specifically, cigarette smoking and infection increase the elastase burden in the lung, thus increasing lung degradation [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/4\" class=\"abstract_t\">4</a>]. In addition, the polymers of &quot;Z&quot; antitrypsin are chemotactic for neutrophils, which may contribute to local inflammation and tissue destruction in the lung [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/8\" class=\"abstract_t\">8</a>].</p><p>The pathogenesis of the liver disease is quite different and is called a &quot;toxic gain of function.&quot; The liver disease results from the accumulation within the hepatocyte of unsecreted variant AAT protein. Only those genotypes associated with pathologic polymerization of AAT within the endoplasmic reticulum of hepatocytes (eg, PI*ZZ type AATD) produce disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/9-11\" class=\"abstract_t\">9-11</a>]. Most patients with liver disease due to AATD are homozygous for the Z allele (ie, PI*ZZ); liver disease does not occur in null homozygotes who have severe deficiency of AAT, but no intra-hepatocytic accumulation. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Hepatic disease'</a>.)</p><p class=\"headingAnchor\" id=\"H544414719\"><span class=\"h2\">AAT genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AATD is inherited by autosomal co-dominant transmission, meaning that affected individuals have inherited an abnormal AAT gene from each parent. The gene that encodes AAT is called SERPINA1 (MIM +107400) and is located on the long arm of chromosome 14 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian#H9\" class=\"medical medical_review\">&quot;Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)&quot;, section on 'Autosomal recessive'</a>.)</p><p>At least 150 alleles of AAT (SERPINA1) have been identified, and each has a letter code based upon electrophoretic mobility of the protein produced. The normal allele is referred to as &quot;M.&quot; As AAT is a protease inhibitor (a member of the serpin family of proteins), the designation &quot;PI&quot; denotes &quot;protease inhibitor&quot; and the letters denotes the alleles that are present. Thus, &quot;PI*MM&quot; refers to homozygosity for the normal gene, while PI*ZZ denotes homozygosity for the Z allele, the most common mutation in the SERPINA1 gene that leads to AAT deficiency [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/12\" class=\"abstract_t\">12</a>]. The &quot;Z&quot; point mutation Glu342Lys (or substitution of a lysine for a glutamic acid at position 342 on the AAT molecule) is in the hinge region of the AAT molecule, which causes an increased tendency to polymerization and aggregation.</p><p>Some individuals have compound heterozygosity, meaning that they carry two different mutations of the same gene. For example, patients with AATD may have an &quot;S&quot; mutation (which is characterized by a single amino acid substitution of a valine for a glutamic acid as position 264) in the PI gene on one chromosome 14 and a &quot;Z&quot; mutation on the other chromosome 14; this pattern is indicated by PI*SZ (<a href=\"image.htm?imageKey=PULM%2F103267\" class=\"graphic graphic_table graphicRef103267 \">table 1</a>). While PI*SS is not associated with an increased risk for emphysema, PI*SZ heterozygotes are at increased risk, especially if they smoke [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/13-15\" class=\"abstract_t\">13-15</a>]. (See <a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian#H9\" class=\"medical medical_review\">&quot;Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)&quot;, section on 'Autosomal recessive'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">AAT phenotypes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AAT phenotyping is based on the electrophoretic mobility of the proteins produced by the various abnormal AAT alleles. Genotyping is performed by identifying specific alleles in DNA, eg, by polymerase chain reaction tests or by gene sequencing. Variants of AAT can be categorized into four basic groups:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normal</strong> &ndash; Normal alleles are associated with normal levels of AAT and normal function. The family of normal alleles is referred to as M and the normal genotype is MM.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Deficient</strong> &ndash; Deficient alleles are associated with plasma AAT levels less than 35 percent of the average normal level. The most common deficient allele associated with emphysema is the Z allele, which is carried by approximately 2 to 3 percent of the Caucasian population in the United States.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Null</strong> &ndash; Null alleles lead to no detectable AAT protein in the plasma. Individuals with the null genotype are the least common and are at risk for the most severe form of associated lung disease but not liver disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dysfunctional</strong> &ndash; Dysfunctional alleles produce a normal quantity of AAT protein but the protein does not function properly (eg, PI*F).</p><p/><p>Individuals with genotypes associated with serum AAT levels below a &quot;protective threshold&quot; value, widely considered to be 57 <span class=\"nowrap\">mg/dL,</span> are considered to be at increased risk for emphysema (<a href=\"image.htm?imageKey=PULM%2F103267\" class=\"graphic graphic_table graphicRef103267 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/16-18\" class=\"abstract_t\">16-18</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H286475241\"><span class=\"h2\">Heterozygous variants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Data are conflicting regarding the risk of emphysema among PI*MZ heterozygotes. </p><p>Studies of nonsmoking PI*MZ heterozygotes show discordant results with the best designed studies suggesting increased risk for emphysema in PI*MZ smokers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/19-25\" class=\"abstract_t\">19-25</a>]:</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In supportive studies, a comparison between individuals in the Lung Health Study with either rapid or slow decline in forced expiratory volume in one second (FEV<sub>1</sub>) showed that the MZ phenotype was associated with rapid decline (odds ratio 2.8, p = 0.03) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/19\" class=\"abstract_t\">19</a>]. Also, a longitudinal study showed a slightly greater annual decrease in FEV<sub>1</sub> in individuals with the MZ genotype compared with those who have the MM genotype (25 versus 21 <span class=\"nowrap\">mL/year,</span> p = 0.048) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/20\" class=\"abstract_t\">20</a>]. The odds ratio for developing airflow obstruction was 1.3 in the MZ heterozygotes compared with normal MM homozygotes. The increase in chronic obstructive pulmonary disease (COPD) risk among PI*MZ heterozygotes may be limited to those with a symptomatic PI*ZZ first-degree relative [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In an analysis of data from case-control and multicenter family studies, individuals with PI*MZ, compared to those with PI*MM, had a slightly lower ratios for FEV<sub>1</sub><span class=\"nowrap\">/forced</span> vital capacity (FVC) or FEV<sub>1</sub><span class=\"nowrap\">/vital</span> capacity, but no difference in FEV<sub>1</sub> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A population study of PI*MZ heterozygotes from the Tucson Epidemiologic Study of Airways Obstructive Diseases failed to show any increased risk of developing airflow obstruction in these MZ individuals [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/23\" class=\"abstract_t\">23</a>]. Also, a meta-analysis highlights the inconsistency of results from available studies [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/24\" class=\"abstract_t\">24</a>], with studies using categorical outcomes generally showing an increased risk and those using continuous measures (eg, FEV<sub>1</sub>) not showing an excess risk in PI*MZ heterozygotes. Relatively few of the available studies adjusted for smoking status and those that did tended to show a smaller risk (odds ratio 1.61, 95% CI 0.92-2.81).</p><p/><p>Studies among ever-smoking PI*MZ individuals suggest an increased risk of COPD: </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the multiethnic COPDGene study of 8271 current and former smokers with &ge;10 years of smoking, PI*MZ subjects had significantly lower FEV<sub>1</sub> percent predicted (68&thinsp;&plusmn;&thinsp;28 versus 75&thinsp;&plusmn;&thinsp;27; P&thinsp;=&thinsp;0.0005) and FEV<sub>1</sub><span class=\"nowrap\">/FVC</span> ratio (0.59&thinsp;&plusmn;&thinsp;0.18 versus 0.63&thinsp;&plusmn;&thinsp;0.17; P&thinsp;=&thinsp;0.0008), and also more radiographic emphysema, than Z-allele noncarriers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent2\">Of note, the PI*MZ genotype was identified in 0.8 percent of non-Hispanic African American (NHAA) participants [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/26\" class=\"abstract_t\">26</a>]. Furthermore, FEV<sub>1</sub> and FEV<sub>1</sub><span class=\"nowrap\">/FVC</span> percent predicted values were lower among PI*MZ NHAA individuals, than those with PI*MM.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A study of 196 non-index relatives of PI*MZ individuals showed that compared with PI*MM relatives, PI*MZ relatives demonstrated lower FEV<sub>1</sub><span class=\"nowrap\">/FVC</span> ratios and post-bronchodilator FEV<sub>1</sub> percent predicted than PI*MM relatives and, in a categorical analysis, a higher prevalence of COPD was observed in PI*MZ individuals (OR 5.10, 95% CI, 1.81&ndash;14.33) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/25\" class=\"abstract_t\">25</a>]. When stratified by smoking status, these differences were observed only in ever-smoking PI*MZ individuals.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although alpha-1 antitrypsin deficiency (AATD) is generally considered to be rare, estimates that 80,000 to 100,000 individuals in the United States have severe deficiency of AAT suggest that the disease is under-recognized [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/27,28\" class=\"abstract_t\">27,28</a>]. The prevalence of AAT varies considerably from one country to another [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/29\" class=\"abstract_t\">29</a>]; however, it is estimated that more than 3 million people worldwide have allele combinations associated with severe deficiency of AAT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/30,31\" class=\"abstract_t\">30,31</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Prevalence</strong> &ndash; Two lines of evidence support prevalence estimates indicating that AATD is approximately as common as cystic fibrosis:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>One study evaluated a sample of 965 patients with chronic obstructive pulmonary disease (COPD); severe deficiency of AAT was found in 2 to 3 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/32\" class=\"abstract_t\">32</a>]. Extrapolating to the United States population of 2.1 million individuals with emphysema (based on the National Health Interview Survey [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/33\" class=\"abstract_t\">33</a>]), 40,000 to 60,000 Americans would be expected to have emphysema caused by AATD.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Direct population screening studies indicate that the prevalence of individuals with the PI*Z phenotype and resultant severe deficiency of AAT ranges from one in 1575 to one in 5097 individuals [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/34-37\" class=\"abstract_t\">34-37</a>]. Based upon the United States population of approximately 320 million, 80,000 to 100,000 severely AAT deficient individuals would be expected. This estimate includes both symptomatic and asymptomatic patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Unrecognized deficiency</strong> &ndash; Several studies indicate that AATD is far less familiar to many clinicians than its prevalence would suggest. Investigators in one report, for example, estimated that there were 700 PI*ZZ individuals in St. Louis, based upon sampling of 20,000 blood specimens submitted to the St. Louis blood bank; only 28 of these individuals (4 percent) had been identified [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/36\" class=\"abstract_t\">36</a>]. Unrecognized individuals with severe deficiency of AAT probably comprise two separate groups: those with no clinical manifestations despite severe deficiency; and those with disease in whom the underlying AAT deficiency has not been recognized. The relative proportion of these two groups remains unknown.</p><p/><p>Many studies have identified under-recognition of AATD in symptomatic patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/27,28,38,39\" class=\"abstract_t\">27,28,38,39</a>]. A 5 to 8 year delay between the first symptom and recognition of AAT deficiency has been found in studies performed over a span of 18 years (to 2013), indicating that under-recognition persists despite extensive educational efforts and the publication of evidence-based guidelines for diagnosis and management of AATD [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5,27,28,39\" class=\"abstract_t\">5,27,28,39</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">RISK FACTORS FOR LUNG DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with phenotypes associated with plasma alpha-1 antitrypsin (AAT) levels below the protective threshold of 11 <span class=\"nowrap\">micromol/L</span> (approximately 57 <span class=\"nowrap\">mg/dL</span> using nephelometry and 80 <span class=\"nowrap\">mg/dL</span> by radial immunodiffusion) are considered to have severe deficiency of AAT and are at risk for emphysema [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/1,5,40\" class=\"abstract_t\">1,5,40</a>]. As noted above, a number of AAT mutations are associated with severe deficiency (<a href=\"image.htm?imageKey=PULM%2F57264\" class=\"graphic graphic_table graphicRef57264 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/16-18\" class=\"abstract_t\">16-18</a>]. </p><p>Severe deficiency of AAT poses a strong risk factor for early-onset emphysema, but not every severely deficient individual is destined to develop emphysema. Risk factors for emphysema include cigarette smoking, dusty occupational exposure, a parental history of COPD, and a personal history of asthma, chronic bronchitis, or pneumonia [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/41,42\" class=\"abstract_t\">41,42</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cigarette smoking </strong>increases the risk of developing fixed airflow obstruction and can markedly accelerate the onset of dyspnea by as much as 19 years. In three studies, for example, the age at onset of dyspnea was 48 to 54 years in nonsmokers versus 32 to 40 years in smokers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/43-45\" class=\"abstract_t\">43-45</a>]. In individuals with the PI*SZ phenotype, cigarette smoking is a particularly important risk factor for the development of COPD, which rarely occurs in nonsmokers with this phenotype [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/46,47\" class=\"abstract_t\">46,47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Occupational and other exposures</strong> &ndash; The precise role of occupational exposures in accelerating the loss of lung function in AATD is also incompletely understood. One study found a link between self-reported exposure to mineral dust and reduced lung function in PI*ZZ patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/48\" class=\"abstract_t\">48</a>], while a second trial suggested that agricultural work and the use of domiciliary kerosene are also independently associated with a more rapid loss of lung function [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/49\" class=\"abstract_t\">49</a>]. Among New York City Fire Department rescue workers who were exposed to respirable particulates and combustion by-products following the World Trade Center collapse, those with even mild or moderate deficiency of AAT (eg, PI*MZ, PI*SZ, and PI*MS) had a more rapid decline in FEV<sub>1</sub> over the next four years than those with normal AAT levels [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Asthma</strong> &ndash; There is an uncertain relationship between severe deficiency of AAT and asthma<strong> </strong>[<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/51\" class=\"abstract_t\">51</a>]. Studies have not shown an increased prevalence of AATD among asthmatics. However, in a large cohort study of over 1000 patients with severe deficiency of AAT, 21 percent of patients met diagnostic criteria for asthma [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/52\" class=\"abstract_t\">52</a>]. The presence of asthma was not independently associated with an accelerated decline in pulmonary function [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"headingAnchor\" id=\"H1551012490\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main clinical manifestations of alpha-1 antitrypsin (AAT) deficiency relate to three separate organs: the lung, the liver, and, much less often, the skin. Sporadic reports indicate other clinical conditions also may accompany AATD. The extrapulmonary manifestations of AATD are discussed separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Clinical presentation of lung disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentation of emphysema due to AAT deficiency has many features in common with usual COPD. Dyspnea is the most common symptom, and many patients report cough, phlegm production, and wheezing, either chronically or with upper respiratory tract infections [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/45,53-55\" class=\"abstract_t\">45,53-55</a>]. Bronchodilator responsiveness (defined as a post-bronchodilator forced expiratory volume in one second [FEV<sub>1</sub>] rise of 200 mL and 12 percent) is common with or without chronic sputum production. </p><p>Two features of emphysema associated with severe deficiency of AAT that may be distinctive are onset at a younger age and a basilar-predominant pattern of emphysema (<a href=\"image.htm?imageKey=PULM%2F61623\" class=\"graphic graphic_table graphicRef61623 \">table 3</a>), although substantial variability is noted among individuals [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The onset of airflow limitation typically occurs at a younger age in AAT-deficient individuals than in non-AAT-deficient individuals, who usually present in the sixth and seventh decades of life. In the National Heart, Lung, and Blood Institute-sponsored Registry for Patients with Severe Deficiency of Alpha-1 Antitrypsin, for example, the mean (&plusmn; SD) FEV<sub>1</sub> in 1129 participants was 43 &plusmn; 30 percent of predicted and their mean age was 46 &plusmn; 11 years [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/54\" class=\"abstract_t\">54</a>]. Similarly, an earlier series of 246 PI*ZZ adults found that chronic obstructive pulmonary disease was present in 74.8 percent of the participants, whose median age was approximately 52 years [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emphysema associated with AATD often shows a characteristic chest radiographic pattern, in which bullous changes are more prominent at the lung bases than at the apices (<a href=\"image.htm?imageKey=PULM%2F65594\" class=\"graphic graphic_diagnosticimage graphicRef65594 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/56,57\" class=\"abstract_t\">56,57</a>]. The prevalence of this pattern of &quot;basilar hyperlucency&quot; varies among series; approximately one-third of patients with severe deficiency of AAT have an upper lobe predominant pattern of emphysema that is more characteristic of &quot;usual,&quot; non-AAT deficient COPD [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/2,55,58\" class=\"abstract_t\">2,55,58</a>]. The largest reported series of 165 PI*Z homozygotes examined with plain chest radiographs found that 140 (85 percent) had some radiographic features of emphysema. Virtually all of these patients had emphysematous changes that included the lung bases, and 24 percent had emphysematous changes that were limited to the lung bases. More recent imaging studies have used computed tomography [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/58,59\" class=\"abstract_t\">58,59</a>]. In one study of PI*ZZ individuals, emphysematous abnormalities were most prominent at the bases in 64 percent of patients and at the apices in 36 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/58\" class=\"abstract_t\">58</a>]. In another case series examining CT scan findings, emphysematous changes were less prominent overall and more likely to be upper lung zone predominant in PI*SZ individuals than PI*ZZ homozygotes, despite comparable physiologic impairment [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p>Spontaneous secondary pneumothorax may be the presenting manifestation of AAT deficiency or a complication of known disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/60-64\" class=\"abstract_t\">60-64</a>].</p><p>Bronchiectasis has also been associated with severe deficiency of AAT. In one study, for example, bronchiectasis was present in 11.3 percent of 246 PI*Z homozygotes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/43\" class=\"abstract_t\">43</a>]. The estimated prevalence in other reports has varied widely from 2 to 43 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/47,65\" class=\"abstract_t\">47,65</a>]. The relationship between AATD and bronchiectasis remains incompletely understood, and the mechanism by which AATD could produce the latter is debated. Bronchiectasis seems to occur most commonly in lobes with higher emphysema scores, suggesting that altered airway architecture may contribute [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/65\" class=\"abstract_t\">65</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-bronchiectasis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of bronchiectasis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H243690729\"><span class=\"h2\">Clinical presentation of extrapulmonary disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with at risk alleles (eg, Z, S[iiyama], and M[malton]) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma, the former often occurring without antecedent childhood liver disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Hepatic disease'</a>.)</p><p>Other extrapulmonary manifestations of AATD include panniculitis (hot, painful, red nodules or plaques characteristically on the thigh or buttocks) and possibly vasculitis, inflammatory bowel disease, intracranial and intra-abdominal aneurysms, fibromuscular dysplasia, and glomerulonephritis, which are discussed separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1551012802\"><span class=\"h1\">EVALUATION AND DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All adults with persistent airflow obstruction on spirometry should be tested for AATD, especially those from geographic areas with a high prevalence of AATD [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/66,67\" class=\"abstract_t\">66,67</a>]. Additional features that should especially lead clinicians to test for AATD include (<a href=\"image.htm?imageKey=PULM%2F61623\" class=\"graphic graphic_table graphicRef61623 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emphysema in a young individual (eg, age &le;45 years)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emphysema in a nonsmoker or minimal smoker</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emphysema characterized by predominant basilar changes on the chest radiograph</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A family history of emphysema <span class=\"nowrap\">and/or</span> liver disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical findings or history of panniculitis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical findings or history of unexplained chronic liver disease</p><p/><p>The diagnosis of severe deficiency of AAT is confirmed by demonstrating a serum level below 11 <span class=\"nowrap\">micromol/L</span> (approximately 57 <span class=\"nowrap\">mg/dL</span> by nephelometry) in combination with a severe deficient phenotype, generally determined by isoelectric focusing, or genotype, assessed by testing for the most common deficient alleles (ie, S, Z, I, F). The one uncommon genotype that can produce normal serum AAT levels but pose emphysema risk is PI*FF, in which the F allele is quantitatively normal but functionally impaired in binding neutrophil elastase [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/18\" class=\"abstract_t\">18</a>]. On the other hand, if one is evaluating for the presence of particular mutations, genotyping is necessary to identify heterozygotes and mutations that have incomplete expressivity [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H1551012796\"><span class=\"h2\">Laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Traditionally, laboratory testing for the diagnosis of AATD used initial assessment of the serum level; if the level was low, the electrophoretic mobility of the AAT protein was assessed to determine the specific AAT variant or phenotype (<a href=\"image.htm?imageKey=PULM%2F104220\" class=\"graphic graphic_algorithm graphicRef104220 \">algorithm 1</a>). With the advent of molecular techniques for genotyping and the use of dried blood spots, various potential algorithms may be followed for diagnosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/69\" class=\"abstract_t\">69</a>]. As an example, a dried blood spot may be sent for simultaneous testing of the AAT level by nephelometry and genotyping for the most common variants.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Serum levels</strong> &ndash; Serum levels of AAT can be assessed by nephelometry or, less often, latex-enhanced immunoturbidimetric assay; radial immunodiffusion and rocket immunoelectrophoresis are no longer used [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"abstract_t\">5</a>]. These tests quantify the amount of AAT protein in serum, but have a low sensitivity for detecting heterozygotes (carriers) of AAT deficiency genes. A reasonable threshold for differentiating normal Pi*MM from other genotypes with one or more deficient alleles is 18.4 <span class=\"nowrap\">micromol/L</span> (100 <span class=\"nowrap\">mg/dL)</span> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5,17,70\" class=\"abstract_t\">5,17,70</a>].</p><p/><p class=\"bulletIndent1\">Population studies suggest a minimum plasma threshold of 11 <span class=\"nowrap\">micromol/L</span> (corresponding to 57 <span class=\"nowrap\">mg/dL</span> by nephelometry), below which there is insufficient AAT to protect the lung, leading to an increased risk of developing emphysema. Most patients below this threshold level are homozygous for the Z allele (designated PI*ZZ) (<a href=\"image.htm?imageKey=PULM%2F57264\" class=\"graphic graphic_table graphicRef57264 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\">The different tests have slightly different normal ranges and the optimal cut-off point for detecting AATD varies somewhat with the test. For immune turbidimetry, a reasonable cut-point is between 100 and 113 <span class=\"nowrap\">mg/dL</span> (18.4 to 21 <span class=\"nowrap\">micromol/L)</span> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/71\" class=\"abstract_t\">71</a>]. In an American study using nephelometry, the cut-off with the greatest area under the receiver operating curve (ROC) was 120 <span class=\"nowrap\">mg/dL</span> (22 <span class=\"nowrap\">micromol/L)</span>. Given these variations in test results, it is essential to know the range of normal values for the test used in a given patient.</p><p/><p class=\"bulletIndent1\">At times of inflammation, serum levels can overestimate the AAT level, as AAT is an acute phase reactant. An acute phase reaction is unlikely to mask AATD in those with the PI*ZZ genotype, but can elevate AAT levels into the normal range in PI*MZ and PI*SZ heterozygotes. </p><p/><p class=\"bulletIndent1\">The normal plasma concentration of AAT ranges from 80 to 220 <span class=\"nowrap\">mg/dL</span> (20 to 48 <span class=\"nowrap\">micromol/L</span> using nephelometry or 150 to 350 <span class=\"nowrap\">mg/dL</span> by radial immunodiffusion). However, given the variability in reference ranges, patients with a serum AAT level below 100 <span class=\"nowrap\">mg/dL</span> (18.4 <span class=\"nowrap\">micromol/L)</span> should be evaluated further with isoelectric focusing or genotyping. Our practice is to test for serum level and genotype in all patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Isoelectric focusing</strong> &ndash; Isoelectric focusing is the gold standard blood test for identifying AAT variants, which migrate differently at different rates under isoelectric focusing. With the availability of genotyping and gene sequencing, isoelectric focusing is performed less often, but is still useful for rare variants (eg, F, I, P) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"abstract_t\">5</a>]. The initial designation of abnormal AAT proteins was based on the speed of migration of the protein variants: M migrates in the middle; S has slow migration and stays closer to the cathode; F migrates fast to the anode; the Z phenotype migrates most slowly and is called &quot;Z&quot; because it is last. Interpretation of isoelectric focusing tests is complicated by the appearance of multiple minor bands for each of the various alleles, absence of protein in patients with null alleles, and M-like alleles (eg, M[Malton]). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Genotyping</strong> &ndash; Genotyping of the protease inhibitor (Pi) locus is generally performed on a blood sample (dried blood spot or whole blood) using polymerase chain reaction (PCR) technology or restriction fragment length polymorphisms (RFLP) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/68,72\" class=\"abstract_t\">68,72</a>]. These tests can detect the most common known variants (F, I, S, Z) when the laboratory test targets these alleles. Alleles that are not tested for by the laboratory cannot be detected; in interpreting laboratory test results, clinicians should be aware of which alleles are interrogated by the laboratory. Not finding an abnormal allele that is not tested for does not exclude the presence of that allele.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gene sequencing</strong> &ndash; Sequencing of exonic DNA is used when available primers for PCR and RFLP testing fail to determine the genetic variant, which is more likely to occur with rare variants or null alleles. Gene sequencing is prudent when the serum level and the reported genotype seem discordant or when the patient's clinical features cannot be explained by the reported genotype.</p><p/><p class=\"headingAnchor\" id=\"H1551012823\"><span class=\"h2\">Pulmonary function testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary function testing is used to assess the presence and severity of lung disease. In these patients, we typically obtain spirometry before and after bronchodilator, lung volumes, and a diffusing capacity for carbon monoxide [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/67\" class=\"abstract_t\">67</a>]. If the diffusing capacity for carbon monoxide (DLCO) is below normal or if the patient reports exertional dyspnea, a six-minute walk test is often obtained. (See <a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">&quot;Overview of pulmonary function testing in adults&quot;</a>.) &#160;</p><p>Patients with airflow limitation and a forced expiratory volume in one second (FEV<sub>1</sub>) &lt;80 percent of predicted post-bronchodilator are candidates for augmentation therapy. (See <a href=\"topic.htm?path=treatment-of-alpha-1-antitrypsin-deficiency#H3522025352\" class=\"medical medical_review\">&quot;Treatment of alpha-1 antitrypsin deficiency&quot;, section on 'Patient selection'</a>.)</p><p class=\"headingAnchor\" id=\"H243690742\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chest imaging is used to determine the pattern and extent of emphysema and also exclude other causes of dyspnea. As noted above, the &quot;classic&quot; pattern of emphysema in AATD is basilar predominant emphysematous bullae (<a href=\"image.htm?imageKey=PULM%2F65594\" class=\"graphic graphic_diagnosticimage graphicRef65594 \">image 1</a>), although a range of patterns from basilar predominant to apical predominant emphysema may be seen. The author obtains a plain chest radiograph as part of the initial assessment; some clinicians perform chest computed tomography (CT) scans for initial assessment [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"#H12\" class=\"local\">'Clinical presentation of lung disease'</a> above.)</p><p class=\"headingAnchor\" id=\"H288038013\"><span class=\"h1\">MONITORING ASYMPTOMATIC PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal frequency of monitoring for onset or progression of lung or liver disease in patients with known alpha-1 antitrypsin (AAT) deficiency has not been formally studied.</p><p>For patients with no respiratory symptoms and a normal baseline spirometry (ie, forced expiratory volume in one second [FEV<sub>1</sub>] &ge;80 percent of predicted), spirometry is typically repeated when symptoms change or at 6 to 12 month intervals [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5,67\" class=\"abstract_t\">5,67</a>]. An unexplained decrease in the post-bronchodilator FEV<sub>1</sub> to less than 80 percent predicted is an indication to initiate augmentation therapy. (See <a href=\"topic.htm?path=treatment-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Treatment of alpha-1 antitrypsin deficiency&quot;, section on 'Intravenous augmentation therapy'</a>.)</p><p>Similarly, guidelines have not been established regarding monitoring for liver disease in patients homozygous for PiZ, PiS[iiyama] or PiM[malton]. Our practice is to assess serum aminotransferases (eg, alanine aminotransferase, aspartate aminotransferase), alkaline phosphatase, and bilirubin annually [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/1,73\" class=\"abstract_t\">1,73</a>]. If a chest CT is performed to assess for emphysema, liver and spleen morphology should be examined. Some clinicians also obtain a complete blood count (CBC), looking for thrombocytopenia, and an abdominal ultrasound, looking for cirrhosis, every 6 to 12 months. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Hepatic disease'</a>.) </p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Current understanding of the natural history of alpha-1 antitrypsin (AAT) deficiency is patchy, with some aspects being reasonably clear and others still murky [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"abstract_t\">5</a>]. It is well-documented that the rate of decline in lung function is strongly dependent on cigarette smoking.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">First four decades of life</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Within the first four decades of life, liver dysfunction is the major threat to the health of affected individuals, and pulmonary dysfunction is less of a concern [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/74,75\" class=\"abstract_t\">74,75</a>]. In the largest study, 90 PI*ZZ and 40 PI*SZ subjects (approximately 20 percent had smoked at some time) had normal lung function on spirometry at age 30 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/76\" class=\"abstract_t\">76</a>], but some evidence of emphysema on chest computed tomography at age 32 among ever-smokers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/77\" class=\"abstract_t\">77</a>]. Later follow-up of this cohort at a median age of 39 showed that the few PI*ZZ smokers had a higher prevalence of COPD (67 percent) than the never or former smokers (5 to 8 percent) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/78\" class=\"abstract_t\">78</a>]. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Hepatic disease'</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Later decades</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beyond the first four decades of life, the natural history of individuals with severe deficiency of AAT is less clear, and survival estimates for subjects with severe deficiency of AAT vary among series, presumably due to differences in study populations. Relatively normal survival appears possible for nonsmoking asymptomatic individuals, although long-term follow-up in a population-based study is needed for confirmation [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/79,80\" class=\"abstract_t\">79,80</a>]. The favorable prognosis for nonsmokers is consistent with expectations that many individuals with severe deficiency are asymptomatic and therefore escape medical attention. In comparison, approximately 40 percent of adults with PI*ZZ have histologically significant liver injury and cirrhosis at the time of death. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H2\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Hepatic disease'</a>.)</p><p>The rate of decline in lung function is strongly affected by cigarette smoking. Available estimates of the yearly decline in forced expiratory volume in one second (FEV<sub>1</sub>) among smokers range from as low as 42 to as high as 317 mL per year, compared with 44 to 110 mL per year in nonsmokers or ex-smokers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/2,45,81-85\" class=\"abstract_t\">2,45,81-85</a>]. The Registry of Patients with Severe Deficiency of Alpha-1 Antitrypsin, an NHLBI-sponsored multicenter study of 1129 patients, found an annual FEV<sub>1</sub> decline of 54 mL per year based upon high quality sequential pulmonary function measurements [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/54,86\" class=\"abstract_t\">54,86</a>]. The rate of decline was higher (84 mL per year) among participants with FEV<sub>1</sub> between 50 and 79 percent predicted who were not receiving augmentation therapy. Similar findings were reported by the UK Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/87\" class=\"abstract_t\">87</a>].</p><p>Overall, approximately 90 percent of subjects with severe deficiency of AAT who smoke will develop radiographic emphysema, compared with 65 percent of nonsmokers [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/44\" class=\"abstract_t\">44</a>]. Mortality rates among AAT-deficient individuals have been reported using case series, but not population-based studies [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/2,43,86,88\" class=\"abstract_t\">2,43,86,88</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 37 percent mortality rate was observed in an 11-year follow-up study of 246 PI*Z homozygotes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/43\" class=\"abstract_t\">43</a>]. Most deaths were ascribed to respiratory failure (59 percent), with a minority of patients (13 percent) succumbing to complications of liver disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A second follow-up study (up to 7.2 years) noted a consistent 3 percent annual mortality rate among the 1129 enrollees in the NHLBI-sponsored registry [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/88\" class=\"abstract_t\">88</a>]. Overall survival over the duration of this study was 82 percent. Most deaths were caused by respiratory failure or liver disease (72 and 10 percent, respectively). Mortality was closely associated with pulmonary function, and was greatest for patients with an FEV<sub>1</sub> &lt;15 percent predicted (36 versus 3 percent for patients with FEV<sub>1</sub> &ge;50 percent predicted).</p><p/><p>Studies from the Danish Registry show that, in addition to FEV<sub>1</sub>, smoking status and method of ascertainment (ie, how the subject comes to the attention of the registry) affect survival [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/89-91\" class=\"abstract_t\">89-91</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Survival among smokers and among patients with symptoms was lower than among their nonsmoking asymptomatic counterparts [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/89,91\" class=\"abstract_t\">89,91</a>]. Furthermore, asymptomatic nonsmokers, who were usually identified as relatives of symptomatic AAT-deficient individuals, had a survival rate equal to that of the normal age-matched Danish population.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The FEV<sub>1</sub> was a major determinant of survival in AAT-deficient individuals, with the mortality rising exponentially as FEV<sub>1</sub> falls below 35 percent of the predicted value (<a href=\"image.htm?imageKey=PULM%2F81503\" class=\"graphic graphic_figure graphicRef81503 \">figure 1</a>). As an example, the two-year mortality rate among individuals with FEV<sub>1</sub> values of 15 percent predicted was almost 50 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/90\" class=\"abstract_t\">90</a>].</p><p/><p>Parameters other than FEV<sub>1</sub> have been used to predict mortality in patients with AAT-deficiency [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/92-96\" class=\"abstract_t\">92-96</a>]. As an example, decreased lung density as assessed by chest computed tomographic (CT) scan was associated with increased mortality in a group of 256 AAT-deficient individuals followed for five years at a single center [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/93\" class=\"abstract_t\">93</a>].</p><p class=\"headingAnchor\" id=\"H131227431\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-chronic-obstructive-pulmonary-disease\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Chronic obstructive pulmonary disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alpha-1 antitrypsin (encoded by the SERPINA1 gene, MIM +107400) is a member of the serpin family of protease inhibitors. It protects the lower airways from damage caused by proteolytic enzymes, such as elastase. (See <a href=\"#H2\" class=\"local\">'AAT phenotypes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The normal alpha-1 antitrypsin (AAT) allele is the M allele. Over 150 allelic variants have been described, of which the most common severely deficient variant is the Z allele. (See <a href=\"#H2\" class=\"local\">'AAT phenotypes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe deficiency of AAT is known to affect approximately 100,000 Americans. However, AAT deficiency (AATD) is severely under-recognized, commonly with long intervals between the first symptom and diagnosis. (See <a href=\"#H7\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations of severe deficiency of AAT typically involve the lung (eg, early onset emphysema), liver (eg, cirrhosis), and, rarely, the skin (eg, panniculitis). (See <a href=\"#H1551012490\" class=\"local\">'Clinical manifestations'</a> above and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary function testing typically demonstrates development of airflow limitation, consistent with COPD. Among middle-aged adults with AATD associated with a homozygous Z allele (PI*ZZ), the mean forced expiratory volume in one second (FEV<sub>1</sub>) of predicted is moderately to severely reduced. Partial reversibility of airflow limitation following bronchodilator inhalation is common. (See <a href=\"#H12\" class=\"local\">'Clinical presentation of lung disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emphysema associated with AATD often shows a characteristic radiographic pattern, in which bullous changes are more prominent at the lung bases than at the apices (<a href=\"image.htm?imageKey=PULM%2F65594\" class=\"graphic graphic_diagnosticimage graphicRef65594 \">image 1</a>). However, emphysematous changes may be apical or diffusely distributed in approximately one-third of patients. (See <a href=\"#H12\" class=\"local\">'Clinical presentation of lung disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All adults with persistent airflow obstruction on post-bronchodilator spirometry should be tested for AATD. Features that should especially lead to AAT deficiency testing include emphysema in a young individual (eg, age &le;45 years), emphysema in a nonsmoker or minimal smoker, emphysema characterized by predominant basilar changes on the chest radiograph, a family history of emphysema <span class=\"nowrap\">and/or</span> liver disease, current or prior panniculitis, and current or prior unexplained chronic liver disease. (See <a href=\"#H1551012802\" class=\"local\">'Evaluation and diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of severe deficiency of AAT is confirmed by demonstrating a serum level below 11 <span class=\"nowrap\">micromol/L</span> (approximately 57 <span class=\"nowrap\">mg/dL</span> by nephelometry) in combination with confirmation of a severe deficient phenotype (by isoelectric focusing) or genotype (by polymerase chain reaction for most common alleles or gene sequencing). Testing strategies depend on local preferences (eg, simultaneous or sequential serum level and genotyping). Given the variability in assays, patients with a serum level &lt;100 <span class=\"nowrap\">mg/dL</span> should be evaluated further by isoelectric focusing or genotyping. An example is provided in the algorithm (<a href=\"image.htm?imageKey=PULM%2F104220\" class=\"graphic graphic_algorithm graphicRef104220 \">algorithm 1</a>). (See <a href=\"#H1551012802\" class=\"local\">'Evaluation and diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who have a low AAT level, but no I, S, or Z variants on genotyping or phenotyping, DNA sequencing may be needed to assess for null or other rare deficient alleles. (See <a href=\"#H1551012796\" class=\"local\">'Laboratory testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AATD, pulmonary function tests (eg, spirometry pre and post bronchodilator, lung volumes, diffusing capacity for carbon monoxide) are used to assess the severity of lung disease and monitor disease progression. (See <a href=\"#H1551012823\" class=\"local\">'Pulmonary function testing'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During the first four decades of life, liver dysfunction is the major threat to the health of affected individuals and may present as chronic elevation of liver enzymes or cirrhosis. Liver disease may also develop in adulthood. (See <a href=\"#H14\" class=\"local\">'Natural history'</a> above and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H4\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Risk and natural history'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the four decades of life, patients with severe deficiency of AAT have an accelerated rate of lung function decline, especially with cigarette smoking and some occupational exposures. Estimates of the yearly decline in FEV<sub>1</sub> among smokers range from as low as 42 to as high as 317 mL per year, compared with 44 to 110 mL per year in nonsmokers or ex-smokers. (See <a href=\"#H14\" class=\"local\">'Natural history'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/1\" class=\"nounderline abstract_t\">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/2\" class=\"nounderline abstract_t\">Brantly ML, Paul LD, Miller BH, et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138:327.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/3\" class=\"nounderline abstract_t\">Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004; 59:441.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/4\" class=\"nounderline abstract_t\">Stoller JK, Aboussouan LS. A review of &alpha;1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185:246.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/5\" class=\"nounderline abstract_t\">Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in &alpha;1-antitrypsin deficiency. Eur Respir J 2017; 50.</a></li><li class=\"breakAll\">http://www.omim.org/entry/613490 (Accessed on September 04, 2014).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/7\" class=\"nounderline abstract_t\">Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med 2002; 346:45.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/8\" class=\"nounderline abstract_t\">Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166:377.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/9\" class=\"nounderline abstract_t\">Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357:605.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/10\" class=\"nounderline abstract_t\">Mahadeva R, Chang WS, Dafforn TR, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999; 103:999.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/11\" class=\"nounderline abstract_t\">Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax 2004; 59:529.</a></li><li class=\"breakAll\">http://www.omim.org/entry/107400 (Accessed on September 04, 2014).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/13\" class=\"nounderline abstract_t\">Holme J, Stockley RA. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. Chest 2009; 136:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/14\" class=\"nounderline abstract_t\">Curiel DT, Chytil A, Courtney M, Crystal RG. Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J Biol Chem 1989; 264:10477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/15\" class=\"nounderline abstract_t\">Green CE, Vayalapra S, Hampson JA, et al. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax 2015; 70:939.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/16\" class=\"nounderline abstract_t\">DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59:259.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/17\" class=\"nounderline abstract_t\">Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. &alpha;1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest 2013; 143:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/18\" class=\"nounderline abstract_t\">Sinden NJ, Koura F, Stockley RA. The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote. BMC Pulm Med 2014; 14:132.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/19\" class=\"nounderline abstract_t\">Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001; 163:469.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/20\" class=\"nounderline abstract_t\">Dahl M, Tybjaerg-Hansen A, Lange P, et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med 2002; 136:270.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/21\" class=\"nounderline abstract_t\">Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000; 161:81.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/22\" class=\"nounderline abstract_t\">S&oslash;rheim IC, Bakke P, Gulsvik A, et al. &alpha;&#8321;-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010; 138:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/23\" class=\"nounderline abstract_t\">Silva GE, Sherrill DL, Guerra S, Barbee RA. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest 2003; 123:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/24\" class=\"nounderline abstract_t\">Hersh CP, Dahl M, Ly NP, et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004; 59:843.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/25\" class=\"nounderline abstract_t\">Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in &alpha;1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189:419.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/26\" class=\"nounderline abstract_t\">Foreman MG, Wilson C, DeMeo DL, et al. Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups. Ann Am Thorac Soc 2017; 14:1280.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/27\" class=\"nounderline abstract_t\">Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 2005; 128:1989.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/28\" class=\"nounderline abstract_t\">Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/29\" class=\"nounderline abstract_t\">Blanco I, de Serres FJ, Fernandez-Bustillo E, et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006; 27:77.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/30\" class=\"nounderline abstract_t\">de Serres FJ, Blanco I, Fern&aacute;ndez-Bustillo E. PI S and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi Arch Chest Dis 2007; 67:184.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/31\" class=\"nounderline abstract_t\">de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122:1818.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/32\" class=\"nounderline abstract_t\">Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986; 89:370.</a></li><li class=\"breakAll\">National Center for Health Statistics. National Health Interview Survey, 1985. Statistical Compendium on Adult Diseases, American Lung Association, 1987; p 31.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/34\" class=\"nounderline abstract_t\">Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294:1316.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/35\" class=\"nounderline abstract_t\">O'Brien ML, Buist NR, Murphey WH. Neonatal screening for alpha1-antitrypsin deficiency. J Pediatr 1978; 92:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/36\" class=\"nounderline abstract_t\">Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989; 140:961.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/37\" class=\"nounderline abstract_t\">Spence WC, Morris JE, Pass K, Murphy PD. Molecular confirmation of alpha 1-antitrypsin genotypes in newborn dried blood specimens. Biochem Med Metab Biol 1993; 50:233.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/38\" class=\"nounderline abstract_t\">Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994; 61:461.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/39\" class=\"nounderline abstract_t\">Greulich T, Ottaviani S, Bals R, et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med 2013; 107:1400.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/40\" class=\"nounderline abstract_t\">Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68:1158.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/41\" class=\"nounderline abstract_t\">Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111:982.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/42\" class=\"nounderline abstract_t\">Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007; 62:806.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/43\" class=\"nounderline abstract_t\">Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204:345.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/44\" class=\"nounderline abstract_t\">Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77:14.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/45\" class=\"nounderline abstract_t\">Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1:152.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/46\" class=\"nounderline abstract_t\">Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154:1718.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/47\" class=\"nounderline abstract_t\">Piras B, Ferrarotti I, Lara B, et al. Clinical phenotypes of Italian and Spanish patients with &alpha;1-antitrypsin deficiency. Eur Respir J 2013; 42:54.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/48\" class=\"nounderline abstract_t\">Mayer AS, Stoller JK, Bucher Bartelson B, et al. Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2000; 162:553.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/49\" class=\"nounderline abstract_t\">Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax 1998; 53:939.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/50\" class=\"nounderline abstract_t\">Banauch GI, Brantly M, Izbicki G, et al. Accelerated spirometric decline in New York City firefighters with &alpha;&#8321;-antitrypsin deficiency. Chest 2010; 138:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/51\" class=\"nounderline abstract_t\">Eden E, Mitchell D, Mehlman B, et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am J Respir Crit Care Med 1997; 156:68.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/52\" class=\"nounderline abstract_t\">Eden E, Hammel J, Rouhani FN, et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest 2003; 123:765.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/53\" class=\"nounderline abstract_t\">Black LF, Kueppers F. alpha1-Antitrypsin deficiency in nonsmokers. Am Rev Respir Dis 1978; 117:421.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/54\" class=\"nounderline abstract_t\">A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1994; 106:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/55\" class=\"nounderline abstract_t\">Gishen P, Saunders AJ, Tobin MJ, Hutchison DC. Alpha 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin Radiol 1982; 33:371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/56\" class=\"nounderline abstract_t\">BACHMANN R, LAURELL CB. Electrophoretic and immunologic classification of M-components in serum. Scand J Clin Lab Invest 1963; 15 Suppl 69:11.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/57\" class=\"nounderline abstract_t\">ERIKSSON S. PULMONARY EMPHYSEMA AND ALPHA1-ANTITRYPSIN DEFICIENCY. Acta Med Scand 1964; 175:197.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/58\" class=\"nounderline abstract_t\">Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 2004; 170:1172.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/59\" class=\"nounderline abstract_t\">Bakker ME, Putter H, Stolk J, et al. Assessment of regional progression of pulmonary emphysema with CT densitometry. Chest 2008; 134:931.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/60\" class=\"nounderline abstract_t\">Serapinas D, Obrikyte V, Vaicius D, et al. Alpha-1 antitrypsin deficiency and spontaneous pneumothorax: possible causal relationship. Pneumologia 2014; 63:32.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/61\" class=\"nounderline abstract_t\">Kusu T, Nakagiri T, Minami M, et al. Null allele alpha-1 antitrypsin deficiency: case report of the total pleural covering technique for disease-associated pneumothorax. Gen Thorac Cardiovasc Surg 2012; 60:452.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/62\" class=\"nounderline abstract_t\">Kanazawa S, Kinoshita Y, Nakagawa Y, et al. Pneumothorax associated with alpha1-antitrypsin deficiency. Intern Med 2009; 48:387.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/63\" class=\"nounderline abstract_t\">Ben&iacute;tez Fuentes R, Leal Orozco A, Dom&iacute;nguez Garrido N, Vel&aacute;zquez de Cu&eacute;llar Paracchi M. [Recurrent pneumothorax: its association with alpha-1 trypsin deficiency]. An Pediatr (Barc) 2008; 69:284.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/64\" class=\"nounderline abstract_t\">Lin YC, Chiu WK, Chang H, et al. Spontaneous pneumothorax in flight as first manifestation of alpha-1 antitrypsin deficiency. Aviat Space Environ Med 2008; 79:704.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/65\" class=\"nounderline abstract_t\">Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest 2000; 117:415.</a></li><li class=\"breakAll\">Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. http://www.goldcopd.org (Accessed on March 17, 2016).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/67\" class=\"nounderline abstract_t\">Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obst Pulm Dis 2016; 3:668.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/68\" class=\"nounderline abstract_t\">Snyder MR, Katzmann JA, Butz ML, et al. Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem 2006; 52:2236.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/69\" class=\"nounderline abstract_t\">Miravitlles M, Herr C, Ferrarotti I, et al. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. Eur Respir J 2010; 35:960.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/70\" class=\"nounderline abstract_t\">Ferrarotti I, Thun GA, Zorzetto M, et al. Serum levels and genotype distribution of &alpha;1-antitrypsin in the general population. Thorax 2012; 67:669.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/71\" class=\"nounderline abstract_t\">McElvaney NG. Diagnosing &alpha;1-antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev 2015; 24:52.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/72\" class=\"nounderline abstract_t\">Andolfatto S, Namour F, Garnier AL, et al. Genomic DNA extraction from small amounts of serum to be used for alpha1-antitrypsin genotype analysis. Eur Respir J 2003; 21:215.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/73\" class=\"nounderline abstract_t\">Dawwas MF, Davies SE, Griffiths WJ, et al. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med 2013; 187:502.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/74\" class=\"nounderline abstract_t\">Wall M, Moe E, Eisenberg J, et al. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr 1990; 116:248.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/75\" class=\"nounderline abstract_t\">Sveger T, Piitulainen E, Arborelius M Jr. Lung function in adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr 1994; 83:1170.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/76\" class=\"nounderline abstract_t\">Bernsp&aring;ng E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med 2007; 101:1971.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/77\" class=\"nounderline abstract_t\">Piitulainen E, Montero LC, Nystedt-D&uuml;zakin M, et al. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. COPD 2015; 12:162.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/78\" class=\"nounderline abstract_t\">Piitulainen E, Mostafavi B, Tanash HA. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years. Int J Chron Obstruct Pulmon Dis 2017; 12:495.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/79\" class=\"nounderline abstract_t\">Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008; 63:1091.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/80\" class=\"nounderline abstract_t\">Campos MA, Alazemi S, Zhang G, et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009; 135:600.</a></li><li class=\"breakAll\">Hutchison DC, Tobin MJ, Cooper D, Lowe D. Longitudinal studies in alpha 1-antitrypsin deficiency: A survey by the British Thoracic Society. In: Pulmonary emphysema and proteolysis, Taylor JC, Mittman C (Eds), Academic Press, New York 1987.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/82\" class=\"nounderline abstract_t\">Wu MC, Eriksson S. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ. J Clin Epidemiol 1988; 41:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/83\" class=\"nounderline abstract_t\">Buist AS, Burrows B, Eriksson S, et al. The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI workshop. Am Rev Respir Dis 1983; 127:S43.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/84\" class=\"nounderline abstract_t\">Viskum K, Kok-Jensen A. Criteria for alpha 1-antitrypsin substitution. Lung 1990; 168 Suppl:586.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/85\" class=\"nounderline abstract_t\">Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J 1999; 13:247.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/86\" class=\"nounderline abstract_t\">Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158:49.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/87\" class=\"nounderline abstract_t\">Dawkins PA, Dawkins CL, Wood AM, et al. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33:1338.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/88\" class=\"nounderline abstract_t\">Stoller JK, Tomashefski J Jr, Crystal RG, et al. Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest 2005; 127:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/89\" class=\"nounderline abstract_t\">Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax 1994; 49:695.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/90\" class=\"nounderline abstract_t\">Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J 1994; 7:1985.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/91\" class=\"nounderline abstract_t\">Seersholm N, Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax 1998; 53:265.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/92\" class=\"nounderline abstract_t\">Shaker SB, Stavngaard T, Stolk J, et al. Alpha1-antitrypsin deficiency. 7: Computed tomographic imaging in alpha1-antitrypsin deficiency. Thorax 2004; 59:986.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/93\" class=\"nounderline abstract_t\">Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003; 58:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/94\" class=\"nounderline abstract_t\">Dowson LJ, Newall C, Guest PJ, et al. Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2001; 163:936.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/95\" class=\"nounderline abstract_t\">Dowson LJ, Guest PJ, Hill SL, et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J 2001; 17:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency/abstract/96\" class=\"nounderline abstract_t\">Stolk J, Ng WH, Bakker ME, et al. Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency. Thorax 2003; 58:1027.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1464 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H346591381\" id=\"outline-link-H346591381\">BACKGROUND</a><ul><li><a href=\"#H544414719\" id=\"outline-link-H544414719\">AAT genetics</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">AAT phenotypes</a></li><li><a href=\"#H286475241\" id=\"outline-link-H286475241\">Heterozygous variants</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">EPIDEMIOLOGY</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">RISK FACTORS FOR LUNG DISEASE</a></li><li><a href=\"#H1551012490\" id=\"outline-link-H1551012490\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Clinical presentation of lung disease</a></li><li><a href=\"#H243690729\" id=\"outline-link-H243690729\">Clinical presentation of extrapulmonary disease</a></li></ul></li><li><a href=\"#H1551012802\" id=\"outline-link-H1551012802\">EVALUATION AND DIAGNOSIS</a><ul><li><a href=\"#H1551012796\" id=\"outline-link-H1551012796\">Laboratory testing</a></li><li><a href=\"#H1551012823\" id=\"outline-link-H1551012823\">Pulmonary function testing</a></li><li><a href=\"#H243690742\" id=\"outline-link-H243690742\">Imaging</a></li></ul></li><li><a href=\"#H288038013\" id=\"outline-link-H288038013\">MONITORING ASYMPTOMATIC PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">NATURAL HISTORY</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">First four decades of life</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Later decades</a></li></ul></li><li><a href=\"#H131227431\" id=\"outline-link-H131227431\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/1464|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PULM/104220\" class=\"graphic graphic_algorithm\">- Diagnosis of AAT deficiency</a></li></ul></li><li><div id=\"PULM/1464|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/65594\" class=\"graphic graphic_diagnosticimage\">- Panacinar emphysema chest radiograph</a></li></ul></li><li><div id=\"PULM/1464|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/81503\" class=\"graphic graphic_figure\">- FEV1 and survival AAT deficiency</a></li></ul></li><li><div id=\"PULM/1464|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/103267\" class=\"graphic graphic_table\">- Characteristics of alpha-1 antitrypsin variants</a></li><li><a href=\"image.htm?imageKey=PULM/57264\" class=\"graphic graphic_table\">- Alpha-1 antitrypsin genotypes</a></li><li><a href=\"image.htm?imageKey=PULM/61623\" class=\"graphic graphic_table\">- Clues to severe AAT deficiency</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-bronchiectasis-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of bronchiectasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian\" class=\"medical medical_review\">Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">Overview of pulmonary function testing in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-chronic-obstructive-pulmonary-disease\" class=\"medical medical_society_guidelines\">Society guideline links: Chronic obstructive pulmonary disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">Treatment of alpha-1 antitrypsin deficiency</a></li></ul></div></div>","javascript":null}